We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $12.4B
1-Year Est. Return 64.17%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$13.4B
AUM Growth
-$1.18B
Cap. Flow
-$624M
Cap. Flow %
-4.67%
Top 10 Hldgs %
7.94%
Holding
1,057
New
56
Increased
305
Reduced
416
Closed
75

Top Buys

Rank Stock Value
1
IOSP icon
Innospec
IOSP
+$25.1M
2
HAE icon
Haemonetics
HAE
+$24.2M
3
CALX icon
Calix
CALX
+$22.2M
4
MXCT icon
MaxCyte
MXCT
+$21.3M
5
FRG
Franchise Group, Inc.
FRG
+$21.3M

Sector Composition

Rank Sector Weight
1 Industrials 25.4%
2 Technology 20.93%
3 Financials 15.39%
4 Consumer Discretionary 13.63%
5 Materials 7.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HRTG icon
676
Heritage Insurance Holdings
HRTG
$1.03B
$3.12M 0.02%
457,403
-622,296
-58% -$4.48M
SLAB icon
677
Silicon Laboratories
SLAB
$7.34B
$3.08M 0.02%
22,000
GABC icon
678
German American Bancorp
GABC
$1.87B
$3.06M 0.02%
79,284
-18,572
-19% -$690K
AXNX
679
DELISTED
Axonics, Inc. Common Stock
AXNX
$3.06M 0.02%
47,000
CCNE icon
680
CNB Financial Corp
CCNE
$1.03B
$3.05M 0.02%
125,133
-24,523
-16% -$589K
BDC icon
681
Belden
BDC
$4.35B
$3.02M 0.02%
51,824
+19,692
+61% +$1.06M
GFI icon
682
Gold Fields
GFI
$38.2B
$3M 0.02%
370,000
-482,993
-57% -$4.32M
NPTN
683
DELISTED
NEOPHOTONICS CORP
NPTN
$3M 0.02%
344,400
+10,000
+3% +$91.2K
RGS icon
684
Regis Corp
RGS
$69.8M
$2.99M 0.02%
42,956
-51,534
-55% -$6.77M
UTMD icon
685
Utah Medical Products
UTMD
$238M
$2.95M 0.02%
31,789
-51
-0.2% -$4.5K
EFOR
686
Everforth Inc
EFOR
$1.39B
$2.94M 0.02%
26,000
SGA icon
687
Saga Communications
SGA
$57.3M
$2.92M 0.02%
128,478
UNTY icon
688
Unity Bancorp
UNTY
$600M
$2.91M 0.02%
124,483
-2,842
-2% -$65K
GTYH
689
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
$2.88M 0.02%
382,978
+167,261
+78% +$1.2M
CAC icon
690
Camden National
CAC
$986M
$2.85M 0.02%
59,470
MEDP icon
691
Medpace
MEDP
$17.3B
$2.84M 0.02%
15,000
-568
-4% -$104K
LARK icon
692
Landmark Bancorp
LARK
$203M
$2.82M 0.02%
130,182
-893
-0.7% -$19.3K
PZZA icon
693
Papa John's
PZZA
$682M
$2.79M 0.02%
22,000
FISI icon
694
Financial Institutions
FISI
$804M
$2.79M 0.02%
90,922
+2,004
+2% +$60.6K
PRTS icon
695
CarParts.com
PRTS
$70M
$2.78M 0.02%
17,800
DGICA icon
696
Donegal Group Class A
DGICA
$722M
$2.76M 0.02%
190,776
-2,740
-1% -$41.2K
DFIN icon
697
Donnelley Financial Solutions
DFIN
$1.18B
$2.75M 0.02%
79,369
+10,346
+15% +$342K
VERI icon
698
Veritone
VERI
$112M
$2.75M 0.02%
115,000
+25,000
+28% +$510K
NEU icon
699
NewMarket
NEU
$8.13B
$2.71M 0.02%
8,000
RGLD icon
700
Royal Gold
RGLD
$21.3B
$2.69M 0.02%
28,200

Similar funds

Royce & Associates's Q3 2021 Portfolio in Review

As of Q3 2021, Royce & Associates held 1,057 positions worth $13.4B, down 8.1% from $14.6B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Royce & Associates withdrew a net $624M in Q3 2021, closing 75 positions and reducing 416 holdings. Its most notable exit was SmileDirectClub, Inc. Class A Common Stock, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 25% of assets, up from 25% a quarter earlier, followed by Technology and Financials.

Against the trend, Royce & Associates opened a new position in Calix worth $23.8M.

  • Royce & Associates's largest Q3 2021 buy was Calix: 480,993 shares worth $23.8M.
  • Royce & Associates added most to Innospec in Q3 2021, an estimated $25.1M increase.
  • Royce & Associates's biggest Q3 2021 reduction was Kulicke & Soffa, cutting an estimated $37.4M.
  • Royce & Associates fully exited SmileDirectClub, Inc. Class A Common Stock in Q3 2021, selling an estimated $32.3M.
  • Royce & Associates's ten largest holdings make up 7.9% of its $13.4B portfolio in Q3 2021.
  • Royce & Associates opened 56 new positions and closed 75 in Q3 2021.
  • Royce & Associates's portfolio value fell 8.1% quarter-over-quarter to $13.4B.

Based on Royce & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.